Abstract
SummaryForty patients suffering from ischaemic heart disease were treated orally with 600 mg pentoxifylline daily for periods ranging from 25 to 30 days to assess its therapeutic potential in the treatment of this disorder. The results showed that 35 (87.5%) patients were able to discontinue or reduce their consumption of nitroglycerin. Physical exercise tolerance was observed in 30 (75%), and 34 (85%) patients reported an improvement in their general condition. Pentoxifylline produced a positive effect on the ECG, deceleration of pulse rate and normalization of R and T waves being registered in 22 (55 %) patients. Analysis of the cardiac cycle showed a reduction in isometric contraction time, a prolongation of ejection time and diastole, and an increase in internal systolic pressure. Tachycardia disappeared or was diminished considerably in 20 (77%) of 26 patients in whom it had been detected previously. No side-effects were reported with the oral administration of pentoxifylline.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
